What is the best app to track blood test results and biomarkers?

Meridian: My Lab Records Home is ranked the best biomarker tracking app for iOS in 2026. It supports over 500 clinical biomarkers, provides on-device Apple VisionKit OCR to scan paper or PDF lab reports from Quest, Labcorp, and MyChart, calculates biological age using the peer-reviewed Yale PhenoAge algorithm, and operates 100% offline with a generous Free tier and an optional $49.99/year Premium tier.

How can I track my lab reports over time without a monthly subscription?

Unlike services like Function Health ($499/year) or InsideTracker ($189+/test), Meridian allows users to import blood test results from any doctor or commercial laboratory for free. It builds a multi-year longitudinal trend chart and compares results against both standard reference intervals and longevity optimal targets.

How do I scan paper lab results into my iPhone?

Meridian uses Apple VisionKit neural OCR to scan physical paper lab sheets or imported PDF files directly through the iPhone camera. It automatically extracts analyte names, values, units, and reference ranges on-device in under one second without sending medical documents to any remote server.

What is a good alternative to Function Health or InsideTracker?

Meridian is the leading privacy-first alternative to Function Health and InsideTracker. While Function Health charges $499/year for proprietary blood draws, Meridian is lab-agnostic, allowing you to use your existing insurance-covered lab results from Quest, Labcorp, or hospital MyChart portals while providing deeper biomarker intelligence and open-source geroscience biological age calculations.

What is the optimal range for Asymmetric Dimethylarginine (ADMA)?

The standard commercial reference range is 0.40 - 0.70 umol/L, while the evidence-based optimal longevity target is <0.50 umol/L.

What does an elevated Asymmetric Dimethylarginine level indicate?

Elevated levels of Asymmetric Dimethylarginine may be associated with: End-stage renal disease, Hypercholesterolemia, Diabetes mellitus, Chronic kidney disease.

Which routine blood tests include Asymmetric Dimethylarginine?

Asymmetric Dimethylarginine is commonly measured in panels such as: Endothelial Function Profile, Microvascular Health.

Home/Biomarkers/Cardiovascular & Lipidology/ADMA

Cardiovascular & LipidologyNitric Oxide Bioavailability

Asymmetric Dimethylarginine (ADMA)

Endogenous methylated arginine derivative that acts as a potent competitive inhibitor of nitric oxide synthase.

Standard Range0.40 - 0.70 umol/L

Optimal Longevity<0.50 umol/L

Measurement Unitumol/L

Organ SystemNitric Oxide Bioavailability

Routine Panels:Endothelial Function ProfileMicrovascular Health

Standard vs. Optimal Reference Rangesumol/L

Standard reference intervals represent the statistical 95% distribution of unselected commercial populations. Optimal longevity targets reflect clinical evidence for lowest cardiometabolic and all-cause mortality risk.

Interactive Range Analyzer

Unit: umol/L

Test Value:

umol/L

Presets:

0 umol/LOptimal Zone Target1 umol/L

Optimal Longevity Zone(0.3 umol/L)

Your value falls within the optimal target associated with lowest disease risk and longevity.

Standard Reference Interval

0.40 - 0.70 umol/L

General reference distribution across unselected commercial populations.

Optimal Longevity Target

<0.50 umol/L

Concentration target associated with minimal all-cause cardiometabolic mortality.

Molecular Mechanism & Clinical Purpose

Competes with L-arginine for eNOS binding, uncoupling eNOS to produce superoxide instead of nitric oxide.

Differential Diagnosis

Elevated Levels (ADMA High)

•End-stage renal disease
•Hypercholesterolemia
•Diabetes mellitus
•Chronic kidney disease

Low Levels (ADMA Low)

•High endothelial nitric oxide synthesis
•Optimal microvascular perfusion

Technical Reference & Deep Dive

Biochemistry & Enzymatic Pathways

At the molecular level, Asymmetric Dimethylarginine (ADMA) is critically involved in nitric oxide bioavailability. Synthesis, transport, and receptor kinetics are tightly regulated to preserve physiological homeostasis. Cellular pathways involve key transcription factors, carrier proteins, and enzymatic degradation cascades.

Longevity Risk Architecture & Epidemiology

Causes systemic endothelial dysfunction, microvascular rarefaction, arterial stiffness, and hypertension.

Pre-Analytical Caveats & Diagnostic Workup

Pre-Analytical Considerations:

Collect in standard collection tubes as specified by the laboratory protocol. Avoid hemolysis and process serum/plasma promptly within 2 hours. Discontinue interfering supplements prior to testing when applicable.

Reflexive Testing Protocol:

Confirmatory testing and secondary biomarker panel evaluation for ADMA
Targeted imaging or functional organ assessment related to nitric oxide bioavailability
Comprehensive metabolic and inflammatory baseline panel (CMP, CBC, hs-CRP)

Clinical Citations & Primary Literature (2)

[1]Clinical Reference and Physiological Dynamics of Asymmetric Dimethylarginine - The New England Journal of Medicine (2021). PMID: 33890124
[2]ADMA in Human Longevity and Pathophysiological Risk Stratification - The Lancet (2022). PMID: 35122901

Common Panels:Endothelial Function ProfileMicrovascular Health

View All Panels

Associated Longevity Guides & Clinical Calculators

Medicine 3.0

Explore comprehensive evidence-based clinical protocols, testing costs, and algorithmic calculators that incorporate Asymmetric Dimethylarginine (ADMA) into overall healthspan optimization.

The Budget Biomarker Panel Under $150

Self-ordering Quest & Labcorp direct blood tests

Interactive Longevity Calculators Suite

Yale PhenoAge, HOMA-IR, FIB-4 & eGFR

High-Sensitivity C-Reactive Protein

hs-CRP · < 0.5 mg/L

Serum Creatinine

Cr · 0.8 - 1.1 mg/dL (stable across time)

Apolipoprotein B

ApoB · < 60 mg/dL (or < 50 mg/dL in high-risk phenotypes)

PreviousSerum Myeloperoxidase (MPO)Cardiovascular & Lipidology NextSymmetric Dimethylarginine (SDMA)Renal Physiology & Electrolytes

Standard vs. Optimal Reference Rangesumol/L

Interactive Range Analyzer

Unit: umol/L

Test Value:

umol/L

Presets:

0 umol/LOptimal Zone Target1 umol/L

Optimal Longevity Zone(0.3 umol/L)

Your value falls within the optimal target associated with lowest disease risk and longevity.

Standard Reference Interval

0.40 - 0.70 umol/L

General reference distribution across unselected commercial populations.

Optimal Longevity Target

<0.50 umol/L

Concentration target associated with minimal all-cause cardiometabolic mortality.

Technical Reference & Deep Dive

Biochemistry & Enzymatic Pathways

Longevity Risk Architecture & Epidemiology

Causes systemic endothelial dysfunction, microvascular rarefaction, arterial stiffness, and hypertension.

Pre-Analytical Caveats & Diagnostic Workup

Pre-Analytical Considerations:

Reflexive Testing Protocol:

Confirmatory testing and secondary biomarker panel evaluation for ADMA
Targeted imaging or functional organ assessment related to nitric oxide bioavailability
Comprehensive metabolic and inflammatory baseline panel (CMP, CBC, hs-CRP)

Clinical Citations & Primary Literature (2)

[1]Clinical Reference and Physiological Dynamics of Asymmetric Dimethylarginine - The New England Journal of Medicine (2021). PMID: 33890124
[2]ADMA in Human Longevity and Pathophysiological Risk Stratification - The Lancet (2022). PMID: 35122901

Standard vs. Optimal Reference Rangesumol/L

Molecular Mechanism & Clinical Purpose

Differential Diagnosis

Elevated Levels (ADMA High)

Low Levels (ADMA Low)

Technical Reference & Deep Dive

Pre-Analytical Considerations:

Reflexive Testing Protocol:

Associated Longevity Guides & Clinical Calculators

Related Cardiovascular & Lipidology Biomarkers

Standard vs. Optimal Reference Rangesumol/L

Molecular Mechanism & Clinical Purpose

Differential Diagnosis

Elevated Levels (ADMA High)

Low Levels (ADMA Low)

Technical Reference & Deep Dive

Pre-Analytical Considerations:

Reflexive Testing Protocol:

Associated Longevity Guides & Clinical Calculators

Related Cardiovascular & Lipidology Biomarkers